Omega-3 Fatty Acids for Major Depressive Disorder During Pregnancy

This study has been completed.
Sponsor:
Information provided by:
National Science Council, Taiwan
ClinicalTrials.gov Identifier:
NCT00618865
First received: February 8, 2008
Last updated: NA
Last verified: February 2008
History: No changes posted

February 8, 2008
February 8, 2008
June 2004
June 2004   (final data collection date for primary outcome measure)
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Omega-3 Fatty Acids for Major Depressive Disorder During Pregnancy
Omega-3 Polyunsaturated Fatty Acids in Women With Major Depressive Disorders During Pregnancy

Whether high-dose omega-3 fatty acids supplement would be an effective treatment in patients with major depressive disorder during pregnancy and breast-feeding.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Depressive Disorder
Dietary Supplement: Omega-3 fatty acids
  • Experimental: 1
    omega-3 fatty acid with 2.2 g of eicosapentanoic acid (EPA) and 1.2 g of docosahexanoic acid (DHA)
    Intervention: Dietary Supplement: Omega-3 fatty acids
  • Placebo Comparator: 2
    Placebo (olive oil ethyl esters)
    Intervention: Dietary Supplement: Omega-3 fatty acids
Su KP, Huang SY, Chiu TH, Huang KC, Huang CL, Chang HC, Pariante CM. Omega-3 fatty acids for major depressive disorder during pregnancy: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2008 Apr;69(4):644-51.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
36
June 2004
June 2004   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Eligible participants were pregnant women, aged 18 to 40 years, with major depressive disorder onset between their 16th week (second trimester) and 32nd week (third trimester) of gestation at the Department of Obstetrics.

Exclusion Criteria:

  • Subjects were excluded with a DSM-IV diagnosis of bipolar disorders, psychotic disorders, substance abuse or dependence for at least 3 months, or any Axis-II diagnosis of borderline or antisocial personality disorder.
Female
18 Years to 40 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00618865
NSC 93-2320-B-039-001
No
Kuan-Pin Su, China Medical University Hospital
National Science Council, Taiwan
Not Provided
Not Provided
National Science Council, Taiwan
February 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP